Schizophrenia Clinical Trials

Showing 721-740 of 1,172 trials

First Time in Human Study (FTIH) With Positron Emission Tomography (PET)

NCT01381419

This study described in the present protocol consists of two sections. Part A is the first administration into man to evaluate the safety, tolerability and pharmacokinetics of single ascending doses of GSK1144814. The study is a single-blind, randomised, placebo-controlled design in healthy male and female (of non-childbearing potential) subjects. Part B will be an open-label design in healthy male subjects to assess the GSK1144814 neurokinin-1 (NK1) receptor occupancy by positron emission tomography (PET) scanning with \[11C\]-GR205171

Schizophrenia

GlaxoSmithKline21 participantsStarted Oct 2008

Harrow, Middlesex, United Kingdom

COMPLETED

Neuropsychological Evaluation of Psychiatric and Neurological Patients

NCT00001192

This study will allow researchers to use various types of tests to evaluate cognitive and sensory functions. These tests, referred to as "batteries" will evaluate attention, executive functions, general intellectual functioning, language, memory, motor functions, orientation, personality, selected sensory and perceptual functions, vigilance (alertness), and visual-spatial functions. Children and adult patient will receive different test batteries. The goals of this research study are to; 1. Create descriptions based on the performance of each patient on the test batteries. Then use this information to relate patient behavior to their neurophysiological, neuroradiological, and biochemical descriptions. 2. Define subgroups of patients based on their neurobehavior in order to decrease the variability of psychiatric diagnoses, treatments, and prognoses.

Anxiety DisorderHead InjuryMood Disorder+2 more

National Institute of Mental Health (NIMH)4,300 participantsStarted Oct 1983

Washington D.C., District of Columbia, United States • Bethesda, Maryland, United States • Detroit, Michigan, United States +4 more locations

First Time in Human Study (FTIH) With Positron Emission Tomography (PET)

Neuropsychological Evaluation of Psychiatric and Neurological Patients

Related Searches

fMRI Study of Nicotinic Effect on Neurophysiology of Schizophrenia

Nicotinic Receptor Density in Smoking and Nonsmoking Schizophrenics

Risk Perception in Drug-Dependent Adults With and Without Schizophrenia

Eye Blink Response in Healthy Volunteers and Adults With Schizophrenia

Omega-3 Fatty Acids (Lovaza) for Second Generation Antipsychotic-Associated Hypertriglyceridemia

A Long-term, Extended Treatment Study of Aripiprazole in Pediatric Patients With Schizophrenia

A Short Treatment Study of Aripiprazole in Pediatric Patients With Schizophrenia

Pharmacokinetics, Effect of Food, Safety and Tolerability of a New Tablet Formulation of GSK1144814 in Healthy Subjects

A Repeat Dose Positron Emission Tomography Study With GSK1144814

A Phase I- Sequential Cohort Dosing to Determine Maximum Tolerated Dose in Healthy Male Volunteers.

Study of Lurasidone in Treating Antipsychotic Naive or Quasi-Naive Children and Adolescents

Past Pain Experience and Perception of Experimental Pain

Serotonin 1A Agonists and Cognition in Schizophrenia

Resource-oriented Music Therapy for Psychiatric Patients With Low Therapy Motivation

Relationship Between Neurotransmitter Receptor Polymorphisms, Plasma Concentrations and Clinical Response to Clozapine

RISE (Rehabilitation Intervention for People With Schizophrenia in Ethiopia)

Evaluation of Executive Function With Virtual Reality Among People With Schizophrenia

The Effect of a Community-based LAI-treated Management Model on the Violence Risk of Patients With Schizophrenia